Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • BioMarin Pharmaceutical News

    82,19 € +0,15% +0,12 €
    07:30:50 Uhr L&S RT aktualisieren | Orderbuch | Mehr Kurse »
    WKN: 924801
    ISIN: US09061G1013
    US-Symbol: BMRN
    Typ: Aktie
    Werbung
    Weiter aufwärts?
    Long Hebel 5,64
    MB8CDQ

    BioMarin Pharmaceutical News

    24.04.24 - PR Newswire
    BioMarin Reports Record Financial Results for the First Quarter 2024
    BioMarin Reports Record Financial Results for the First Quarter 2024 PR Newswire
    10.04.24 - PR Newswire
    BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
    BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET PR Newswire
    12.03.24 - PR Newswire
    New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
    New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and ...
    07.03.24 - PR Newswire
    BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
    BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer PR Newswire
    01.03.24 - PR Newswire
    BioMarin Scheduled to Participate in March Investor Conferences
    BioMarin Scheduled to Participate in March Investor Conferences PR Newswire
    22.02.24 - PR Newswire
    BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
    BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024 PR Newswire
    13.02.24 - wallstreet:online Zentralredaktion
    Tech-Analyse: Nvidia und elf weitere Wachstumsperlen, deren KGV für sich spricht!
    Die Nvidia-​Aktie hat ihren Wert im vergangenen Jahr mehr als verdoppelt. Angesichts dieses Laufes könnte man meinen, die Aktie wäre alles andere als günstig bewertet. Das sei ...
    08.02.24 - PR Newswire
    BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET
    BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET PR Newswire
    06.02.24 - PR Newswire
    BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress
    BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-​rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders ...
    03.01.24 - PR Newswire
    BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA
    BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA PR Newswire
    20.12.23 - PR Newswire
    BioMarin Announces Governance Enhancements and Value Creation Initiatives
    BioMarin Announces Governance Enhancements and Value Creation Initiatives PR Newswire
    28.11.23 - PR Newswire
    BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany
    BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-​rvox) for Severe Hemophilia A in ...
    01.11.23 - PR Newswire
    BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
    BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year PR Newswire
    01.11.23 - PR Newswire
    BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer
    BioMarin Announces Retirement of Jean-​Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer PR Newswire
    20.10.23 - PR Newswire
    U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia
    U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia PR Newswire
    17.10.23 - PR Newswire
    BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET
    BioMarin to Host Third-​Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET PR Newswire
    21.09.23 - PR Newswire
    BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
    BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology ...
    15.09.23 - PR Newswire
    BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia
    BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia PR Newswire
    11.09.23 - PR Newswire
    BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York
    BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York PR Newswire
    06.09.23 - PR Newswire
    BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th
    BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th PR Newswire

    Newssuche

    Videos

    newspaper
    24.04.24
    Technical Trading: AUD/USD mit Mega Chance
    AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »